scispace - formally typeset
G

G A Hancock

Researcher at Centers for Disease Control and Prevention

Publications -  7
Citations -  1656

G A Hancock is an academic researcher from Centers for Disease Control and Prevention. The author has contributed to research in topics: Staphylococcus intermedius & Typing. The author has an hindex of 7, co-authored 7 publications receiving 1636 citations.

Papers
More filters
Journal ArticleDOI

Pulsed-field gel electrophoresis as a replacement for bacteriophage typing of Staphylococcus aureus.

TL;DR: A modified, standardized PFGE methodology should enable typing laboratories to obtain rapid, reliable results in 3 to 4 days when starting with an isolated colony on agar media.
Journal ArticleDOI

Comparison of traditional and molecular methods of typing isolates of Staphylococcus aureus.

TL;DR: Phage typing, plasmid DNA restriction analysis, and antibiogram analysis, the techniques most readily available to clinical laboratories, identified 23 to 26 of 29 outbreak-related isolates and assigned 0 to 6 unrelated isolates to outbreak strain types.
Journal ArticleDOI

Characterization of Staphylococci with Reduced Susceptibilities to Vancomycin and Other Glycopeptides

TL;DR: B strains of staphylococci with reduced susceptibility to glycopeptides, such as vancomycin, are best detected in the laboratory by nonautomated quantitative tests incubated for a full 24 h.
Journal ArticleDOI

Characteristics of coagulase-negative staphylococci that help differentiate these species and other members of the family Micrococcaceae

TL;DR: Three simple tests for synergistic hemolysis, adherence to glass, pyroglutamyl-beta-naphthylamide hydrolysis, and susceptibility to a set of five antimicrobial agents for differentiating these species and strains within the species are described.
Journal ArticleDOI

Emergence and control of methicillin-resistant Staphylococcus aureus in a children's hospital and pediatric long-term care facility.

TL;DR: In this paper, the authors evaluated the response to therapy with rifampin alone or in combination with trimethoprim-sulfamethoxazole for MRSA infection.